Dainippon Sumitomo Pharma co., Ltd. And Boston biomedical, Inc. announce strategic partnership for anti-cancer drugs targeting cancer stem cells

Current article ratings:
Patients / public:healthcare Prof:
Dainippon Sumitomo Pharma co., Ltd. ("DSP") and Boston biomedical, Inc. ("BBI"), announced that they have signed an option agreement for BBI608 product for all oncological indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada.

BBI608 is the very malignant cancer stem cells and other heterogeneous cancer cells is an orally administered first-in-class, small molecule anti-cancer drug. In clinical studies to date, BBI608 has shown excellent security, favourable pharmacokinetics and encouraging signs of the anti-cancer activity. BBI608 is in phase I clinical trials in colorectal cancer and phase IB/II clinical trials in multiple solid tumor types.

Under the terms of the agreement, BBI receive $15 of the advance payment, as well as clinical study support for signing. On the basis of the results of clinical trials, DSP who acquires possibility has exclusive rights for the development and marketing for BBI608 in Japan. DSP also has an exclusive negotiations right for the United States and Canada for some time. During this time option agreement numbers DSP maximum $55 million for part of the development costs of BBI608 and for the continuation of the option. Provided DSP could exercise the option for Japan, when the successful clinical development and marketing of BBI608 in Japan, BBI maximum approx. $100million in aggregate, including associated with successful development and marketing, get in addition to licensing fees, milestone payments.

Masayo TADA, President and Chief Executive Officer of DSP, said, "DSP recognizes Oncology, so an area of high unmet medical needs and has already substantial efforts to define it as a large specialty area." We are pleased to enter into this strategic partnership with Boston biomedical in Oncology BBI608 as a differentiated, novel anti-cancer drug development. "The addition of the BBI608 of our research pipeline hopes, DSP his presence in the therapeutic field of cancer increase at the same time contribute to the treatment of cancer patients."

"We look forward to this strategic Oncology partnership with Dainippon Sumitomo Pharma on BBI608," said Chiang j. LI, Chairman and Chief Executive Officer of BBI. "With DSP's outstanding track record of innovative medicine, to bring patients, this partnership marked not only a significant milestone for BBI as we our global development strategy for BBI608, but also an important step towards the translation of cancer stem cells science truly innovative Therapeutics for cancer patients run."

BBI608 and cancer stem cells

BBI608 is a first-in-class, cancer stem cells inhibitor, currently in clinical development. Cancer stem cells (CSCs), is on current cancer therapies, represent an emerging approach to the design of the next generation of Oncology Therapeutics. CSCs are basically responsible for harm growth, metastasis and recurrence. These cells are a subpopulation of cancer cells that have self-renewal ability and can differentiate themselves in the heterogeneous cancer cells, which include most of the tumour mass. CSCs were isolated from almost all major types of cancer and intrinsically resistant to current cancer therapies have been found. Audience-based targeting CSCs, holds advanced therefore big promises cancer treatment essential.

BBI608, inhibits ways by his quiet molecular aim at the same time more important cancer cell Stemness. BBI608 objectives very malignant CSCs and heterogeneous cancer cells. In clinical studies to date, BBI608 has shown excellent security, favourable pharmacokinetics and encouraging signs of the anti-cancer activity against a wide range of tumour types. BBI608 is currently in phase I extension in colorectal cancer and phase IB/II trials in combination with paclitaxel for selected solid tumor types.

Source: Boston biomedical, Inc